BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 21810561)

  • 21. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction].
    Ji Y; Peng T; Wang G; Zhang Y; Cao M; Gao Q; Li S
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1019-1024. PubMed ID: 30269322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant chemotherapy or chemoradiation for patients with advanced adenocarcinoma of the oesophagus? A propensity score-matched study.
    Favi F; Bollschweiler E; Berlth F; Plum P; Hescheler DA; Alakus H; Semrau R; Celik E; Mönig SP; Drebber U; Hölscher AH
    Eur J Surg Oncol; 2017 Aug; 43(8):1572-1580. PubMed ID: 28666624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis and treatment of non-metastatic esophagogastric junction adenocarcinoma: what are the current options?
    Gronnier C; Piessen G; Mariette C
    J Visc Surg; 2012 Feb; 149(1):e23-33. PubMed ID: 22341763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy.
    Haag GM; Czink E; Ahadova A; Schmidt T; Sisic L; Blank S; Heger U; Apostolidis L; Berger AK; Springfeld C; Lasitschka F; Jäger D; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2019 Apr; 144(7):1697-1703. PubMed ID: 30499151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
    Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
    BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
    J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
    Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multidisciplinary approach to esophageal and gastric cancer.
    Stein HJ; Sendler A; Fink U; Siewert JR
    Surg Clin North Am; 2000 Apr; 80(2):659-82; discussions 683-6. PubMed ID: 10836011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
    Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
    J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Role of postoperative chemoradiotherapy in the therapeutic management of adenocarcinomas of the stomach and oesogastric junction].
    Ben Salah H; Bahri M; Dhouib F; Daoud J
    Cancer Radiother; 2016 Dec; 20(8):830-832. PubMed ID: 27793531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
    Liu X; Jin J; Cai H; Huang H; Zhao G; Zhou Y; Wu J; Du C; Long Z; Fang Y; Ma M; Li G; Zhou M; Yin J; Zhu X; Zhu J; Sheng W; Huang D; Zhu H; Zhang Z; Lu Q; Xie L; Zhang Z; Wang Y
    BMC Cancer; 2019 Jun; 19(1):606. PubMed ID: 31221115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
    Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
    Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
    Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X
    BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy for Esophageal Adenocarcinoma.
    Lam KO; Kwong DLW
    Methods Mol Biol; 2018; 1756():19-34. PubMed ID: 29600357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapy in gastric cancer. From an oncological perspective].
    Wilke H; Stahl M
    Chirurg; 2009 Nov; 80(11):1023-7. PubMed ID: 19902288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
    Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
    Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant Therapy Improves Outcomes in Locally Advanced Signet-Ring-Cell Containing Esophagogastric Adenocarcinomas.
    Heger U; Sisic L; Nienhüser H; Blank S; Hinz U; Haag GM; Ott K; Ulrich A; Büchler MW; Schmidt T
    Ann Surg Oncol; 2018 Aug; 25(8):2418-2427. PubMed ID: 29855828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Management of Locally Advanced Junction Esophagogastric Adenocarcinoma.
    Birla R; Hoara P; Caragui A; Cristian M; Constantinoiu S
    Chirurgia (Bucur); 2018; 113(1):38-45. PubMed ID: 29509530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus.
    Moehler M; Baltin CT; Ebert M; Fischbach W; Gockel I; Grenacher L; Hölscher AH; Lordick F; Malfertheiner P; Messmann H; Meyer HJ; Palmqvist A; Röcken C; Schuhmacher C; Stahl M; Stuschke M; Vieth M; Wittekind C; Wagner D; Mönig SP
    Gastric Cancer; 2015 Jul; 18(3):550-63. PubMed ID: 25192931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Multimodal therapy in locally advanced gastric cancer].
    Bölke E; Peiper M; Knoefel WT; Baldus SE; Schauer M; Matuschek C; Gerber PA; Hoff NP; Budach W; Gattermann N; Erhardt A; Scherer A; Buhren BA; Orth K
    Dtsch Med Wochenschr; 2011 Oct; 136(43):2205-11. PubMed ID: 22009175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.